Brandy Rutland
Psychiatric/Mental Health · Jackson, MSNPI 1225628761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 254 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.2% — the pattern of someone who eats at a lot of different presentations.
Across 254 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$508
- Axsome Therapeutics, Inc.$435
- Tris Pharma Inc$416
- AbbVie$401
- Alkermes, Inc.$367
- Teva Pharmaceuticals USA, Inc.$308
- plus $2K from 14 others
What the payments were for
- Food & beverage$4,166100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 33 | $508 |
| Axsome Therapeutics, Inc. | 28 | $435 |
| Tris Pharma Inc | 29 | $416 |
| AbbVie | 25 | $401 |
| Alkermes, Inc. | 20 | $367 |
| Teva Pharmaceuticals USA, Inc. | 20 | $308 |
| Otsuka America Pharmaceutical, Inc. | 19 | $306 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $234 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $220 |
| Supernus Pharmaceuticals, Inc. | 12 | $182 |
| Johnson & Johnson | 5 | $180 |
| Neurocrine Biosciences, Inc. | 9 | $169 |
| Corium, LLC | 8 | $136 |
| Lundbeck LLC | 5 | $99 |
| Avanir Pharmaceuticals, Inc. | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Indivior Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$125
How this compares
$4,166 in reported general payments places this provider in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
See all psychiatric/mental health providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $27,169 |
| RexultiBrexpiprazole | 11 | $16,583 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,205 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $3,460 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 72 | $2,155 |
| Quetiapine Fumarate | 113 | $1,697 |
| Clonazepam | 251 | $1,352 |
| Duloxetine Hcl | 85 | $1,242 |
| Ziprasidone Hcl | 29 | $1,003 |
| Trazodone Hcl | 106 | $921 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 23 | $895 |
| Alprazolam | 108 | $891 |
| Olanzapine | 82 | $795 |
| Buspirone Hcl | 64 | $713 |
| Hydroxyzine Pamoate | 83 | $655 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $401 | $27,16919 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $306 | $16,58311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $234 | $6,20513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 486 psychiatric/mental health providers in Mississippi.
Other psychiatric/mental health in Jackson
- Alanna WrightJackson$58K
- Belinda EdwardsJackson$29K
- Kimberly KelleyJackson$11K
- Tyrah HickmanJackson$5K
- Min Jung KangJackson$5K
- Adriane HarveyJackson$5K
- Ashley KarelVicksburg$129K
- Amanda HamCorinth$64K
- Amanda ThomasTupelo$41K
- Amelia KelleyMeridian$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.